Independent federal agencies were a hallmark of the Progressive Era, designed to operate at arm’s length from elected officials. Over time, however, many of these agencies have accumulated powers that raise serious constitutional concerns—writing rules, enforcing them, and adjudicating disputes internally. In a recent RealClearMarkets piece, Charles Sauer argues that Read more…
In a recent RealClearMarkets article, Charles Sauer uses a football analogy to capture what’s at stake in today’s antitrust debates. Football works because the rules are known in advance and applied consistently. When referees invent new rules mid-game, the integrity of competition collapses. Markets operate the same way. Sauer argues Read more…
President Trump recently floated the idea of imposing a one-year cap on credit card interest rates at 10 President Trump recently floated the idea of imposing a one-year cap on credit card interest rates at 10 percent. Given that Americans currently hold more than $1.2 trillion in credit card debt—and Read more…
As Congress debates whether to extend the Affordable Care Act’s enhanced insurance subsidies—originally enacted as part of the 2021 COVID relief bill—lawmakers face a familiar dilemma: preserve a failing system through temporary fixes or pursue reforms that empower patients and lower costs in the long run. In a recent article Read more…
In a recent RealClearMarkets column, Charles Sauer explains why Netflix’s proposed acquisition of Warner Bros. should be approved—and why it highlights the failure of outdated antitrust thinking in a fast-moving entertainment market. Netflix appears poised to acquire Warner Bros. despite a hostile takeover bid from Paramount Pictures. While the deal Read more…
In a recent RealClearMarkets column, Norm Singleton pushes back against the familiar panic that accompanies every major technological shift in the movie industry—this time aimed at streaming and Netflix’s proposed acquisition of Warner Brothers. Singleton reminds readers that resistance to innovation is nothing new. From the earliest days of sound Read more…
In a recent RealClearMarkets column, Charles Sauer examines the growing push to impose “most favored nation” (MFN) drug pricing through legislation expanding access to home infusion therapy—and explains why importing foreign-style price controls would ultimately hurt patients, not help them. Home infusion therapy allows millions of Americans with cancer, heart Read more…
Elon Musk is learning that in Europe, defending free speech comes at a steep price. In a recent RealClearMarkets column, Charles Sauer examines the European Union’s decision to fine X $140 million under its Digital Services Act (DSA) — a move that looks far less like consumer protection and far Read more…
Alzheimer’s disease is no longer just a medical challenge. It is a looming fiscal crisis—and one the United States is dangerously unprepared to confront. In a recent column published in The Capitalist, Charles Sauer argued that policymakers urgently need to recognize Alzheimer’s as an economic ticking time bomb. Without a Read more…
As Charles Sauer explains in a recent column for RealClearMarkets, the backlash against Netflix’s proposed acquisition of Warner Bros. reflects today’s reflexive antitrust panic—not the realities of competition in the entertainment marketplace. Critics on both the left and right have rushed to portray the deal as a threat to consumers, Read more…